Non-ergot dopamine agonists have become popular for
treating motor complications associated with long-term use of
levodopa-containing drugs. We conducted a retrospective study in which we
identified clinical problems related to use of non-ergot dopamine agonists. The
study included 38 patients with Parkinson’s disease (PD) who suffered the
wearing-off phenomenon and had thus been under non-ergot dopamine receptor
agonist therapy for 1 - 2 years. Some presented with problems such as major
symptoms of PD (30.3%), psychiatric symptoms (24.2%), and postural dysfunction
(21.2%). Comparison between two different non-ergot drugs showed the levodopa
dosage to be greater among patients taking ropinirole than among those taking
pramipexole. In patients with advanced PD, various problematic symptoms can
develop early after administration of a non-ergot dopamine agonist to treat the
wearing-off phenomenon, necessitating identification and treatment of such
symptoms on a patient-to-patient basis.
References
[1]
Ziv, I., Zilkha-Falb, R., Offen, D., Shirvan, A., Barzilai, A. and Melamed, E. (1997) Levodopa Induces Apoptosis in Cultured Neuronal Cells—A Possible Accelerator of Nigrostriatal Degeneration in Parkinson’s Disease? Movement Disorders, 12, 17-23.
https://doi.org/10.1002/mds.870120105
[2]
Rascol, O., Brooks, D.J., Korczyn, A.D., De, Deyn, P.P., Clarke, C.E. and Lang, A.E. (2000) A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinon’s Disease Who Were Treated with Ropinirole or Levodopa. The New England Journal of Medicine, 342, 1484-1491.
https://doi.org/10.1056/NEJM200005183422004
[3]
Parkinson Study Group (2000) Pramipexole vs. Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial. JAMA, 284, 1931-1938.
https://doi.org/10.1001/jama.284.15.1931
[4]
Holloway, R.G., Shoulson, I., Fahn, S., Kieburtz, K., Lang, A., Marek, K., McDermott, M., Seibyl, J., Weiner, W., Much, B., Kamp, C., Welsh, M., Shinaman, A., Pahwa, R., Barclay, L., Hubble, J., LeWitt, P., Miyasaki, J., Suchowersky, O., Stacy, M., Russell, D.S., Ford, B., Hammerstad, J., Riley, D., Standaert, D., Wooten, F., Factor, S., Jankovic, J., Atassi, F., Kurlan, R., Panisset, M., Rajput, A., Rodnitzky, R., Shults, C., Petsinger, G., Waters, C., Pfeiffer, R., Biglan, K., Borchert, L., Montgomery, A., Sutherland, L., Weeks, C., DeAngelis, M., Sime, E., Wood, S., Pantella, C., Harrigan, M., Fussell, B., Dillon, S., Alexander-Brown, B., Rainey, P., Tennis, M., Rost-Ruffner, E., Brown, D., Evans, S., Berry, D., Hall, J., Shirley, T., Dobson, J., Fontaine, D., Pfeiffer, B., Brocht, A., Bennett, S., Daigneault, S., Hodgeman, K., O’Connell, C., Ross, T., Richard, K., Watts, A. and Parkinson Study Group (2004) Pramipexole vs. Levodopa as Initial Treatment for Parkinson Disease: A 4-Year Randomized Controlled Trial. Archives of Neurology, 61, 1044-1053.
https://doi.org/10.1001/archneur.61.7.1044
[5]
Olanow, C.W. and Koller, W.C. (1998) An Algorithm (Decision Tree) for the Management of Parkinson’s Disease: Treatment Guidelines. American Academy of Neurology. Neurology, 50, S1-S57. https://doi.org/10.1212/WNL.50.3_Suppl_3.S1
[6]
Bézard, E., Ferry, S., Mach, U., Stark, H., Leriche, L., Boraud, T., Gross, C. and Sokoloff, P. (2003) Attenuation of Levodopa-Induced Dyskinesia by Normalizing Dopamine D3 Receptor Function. Nature Medicine, 9, 762-767.
https://doi.org/10.1038/nm875
[7]
Foley, P., Gerlach, M., Double, K.L. and Riederer, P. (2004) Dopamine Receptor Agonists in the Therapy of Parkinson’s Disease. Journal of Neural Transmission (Vienna), 111, 1375-1446. https://doi.org/10.1007/s00702-003-0059-x
[8]
Schapira, A.H. (2008) Progress in Neuroprotection in Parkinson’s Disease. European Journal of Neurology, 15, 5-13.
https://doi.org/10.1111/j.1468-1331.2008.02055.x
[9]
Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A., Olanow, C.W., Tanner, C., Marek, K. and Parkinson Study Group (2004) Levodopa and the Progression of Parkinson’s Disease. The New England Journal of Medicine, 351, 2498-2508. https://doi.org/10.1056/NEJMoa033447
[10]
Gibb, W.R. and Lees, A.J. (1988) The Relevance of the Lewy Body to the Pathogenesis of Idiopathic Parkinson’s Disease. Journal of Neurology, Neurosurgery, and Psychiatry, 51, 745-752. https://doi.org/10.1136/jnnp.51.6.745
[11]
Tomlinson, C.L., Stowe, R., Patel, S., Rick, C., Gray, R. and Clarke, C.E. (2010) Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson’s Disease. Movement Disorders, 25, 2649-2653. https://doi.org/10.1002/mds.23429
[12]
Coldwell, M.C., Boyfield, I., Brown, T., Hagan, J.J. and Middlemiss, D.N. (1999) Comparison of the Functional Potencies of Ropinirole and Other Dopamine Receptor Agonists at Human D2 (Long), D3 and D4.4 Receptors Expressed in Chinese Hamster Ovary Cells. British Journal of Pharmacology, 127, 1696-702.
https://doi.org/10.1038/sj.bjp.0702673
[13]
Hauser, R.A., Rascol, O., Korczyn, A.D., Jon, Stoessl, A., Watts, R.L., Poewe, W., De, Deyn, P.P. and Lang, A.E. (2007) Ten-Year Follow-Up of Parkinson’s Disease Patients Randomized to Initial Therapy with Ropinirole or Levodopa. Movement Disorders, 22, 2409-2417. https://doi.org/10.1002/mds.21743
[14]
Hely, M.A., Morris, J.G., Reid, W.G. and Trafficante, R. (2005) Sydney Multicenter Study of Parkinson’s Disease: Non-L-Dopa-Responsive Problems Dominate at 15 Years. Movement Disorders, 20, 190-199. https://doi.org/10.1002/mds.20324
[15]
Katzenschlager, R., Head, J., Schrag, A., Ben-Shlomo, Y., Evans, A., Lees, A.J. and Parkinson’s Disease Research Group of the United Kingdom (2008) Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Initial Treatments in PD. Neurology, 71, 474-480.
https://doi.org/10.1212/01.wnl.0000310812.43352.66
